Allurion Technologies (ALURD) Preferred Stock Liabilities (2022 - 2024)
Allurion Technologies' (ALURD) quarterly Preferred Stock Liabilities came in at $979000.0 in Q3 2024, down 98.31% on a QoQ basis from $58.0 million in Q2 2023.
Allurion Technologies (ALURD) Preferred Stock Liabilities (2022 - 2024) Analysis & Trends
Allurion Technologies (ALURD) has 3 years of Preferred Stock Liabilities data on file, last reported at $979000.0 in Q3 2024.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $979000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $979000.0 (changed N/A YoY) and the FY2022 annual result came in at $58.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $979000.0 in Q3 2024, from $58.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $58.0 million in Q2 2023 to a low of $979000.0 in Q3 2024.
- A 3-year average of $39.0 million and a median of $58.0 million in 2022 frame the typical range for Preferred Stock Liabilities.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | - |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn | - |
| 10 | Allurion Technologies | 49.18 Mn | 44.13 Mn | 1.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 979,000.00 |
| Jun 30, 2023 | 58.03 Mn |
| Dec 31, 2022 | 58.00 Mn |